New Directions in Pharmacoeconomic Research: The Next Step
- PDF / 700,532 Bytes
- 9 Pages / 504 x 719.759 pts Page_size
- 33 Downloads / 237 Views
0092-8615/2002 Copyright 0 2002 Drug Information Association Inc.
NEW DIRECTIONS IN PHARMACOECONOMIC RESEARCH: THE NEXT STEP HIRSCHS. RUCHLIN,PHD Professor of Economics in Public Health and Medicine, Weill Medical College of Cornell University, New York, New York
ERIKJ. DASBACH,PHD Director. Scientific Staff, Health Economic Statistics. Merck Research Laboratories, Blue Bell, Pennsylvania
JOSEPHF. HEYSE,PHD Executive Director. Biostatistics and Research Data SystemsNaccines. Merck Research Laboratories, Blue Bell, Pennsylvania
The United States Food and Drug Administration, m n u g e d care organizations, thirdp a r e pciyers. and national healthcare systems (ire engaged in reviewing pharmacoeconotnic submissions from drug companies. Despite recommendations by various advisor?, conirnittees on methods ,for conducting economic evaluations, differences in opinions cimong the producers of pharnmcorcorronric informarion still exist on the appropriateness of the recornmerrdntiotrs scientifically, as well (is their suitability for intended users. We review the current state of the market for phcirmacoeconomic informarion as well as the key nrethodologic issues facing those performing such analyses. While considerable progress has been nuide establishing rigorous methodsfor conducting economic evaluations, f ~ ~ r t h progress er can be made. This can be accomplished by convening the u.sers and producers of this information. The goal of such a meeting would not be to develop u "one size fits all" standrird but rather to maximize the scientijic integrity of studies by providing broad technical guidance. modifications for digerent audiences. and applicability to n wide variety of healthcare interventions. Key Words: Pharrnacoeconomics; Managed care organizations: Third-party payers; National healthcare systems
INTRODUCTION THE OF programs are a major concern to all purchasers of healthcare, and calls for more rigorous technology assessment are commonplace. Recently, attention has focused primarily on the
Reprint address: Hirsch S. Ruchlin, PhD. Professor of Economics in Public Health and Medicine. Weill Medical College - of cornelluniversity.41 1 East 69th Street-KB319, New York, NY 10021.
field of pharmacoeconomics. For instance, some managed care programs in the United States and national health plans abroad have adopted formal requirements for pharmacoeconomic information that accompanies a submission for determination of placement on their formulary or the level of reimbursement. A recent examDle of this Dhenomenon in the United States is Rxlntelligence, a notfor-profit organization established by the Blue Cross/Blue Shield Association that will perform pharmacoeconomic reviews for all
909
Downloaded from dij.sagepub.com at UNIV OF NEW ORLEANS on June 3, 2015
910
Hirsch S. Kuchlirr. Erik J. l~n.sDuch.mid Joseph I.: Heyse
interested parties. Given the limitations on healthcare resources, the collection and analysis of health economic data is of utmost importance to governments, third-party payers, managed ca
Data Loading...
